key: cord-0707276-v8dghw17
authors: Wood, Emily; Hall, Katherine H.; Tate, Warren
title: Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 ‘long-haulers’?
date: 2020-11-21
journal: Chronic Dis Transl Med
DOI: 10.1016/j.cdtm.2020.11.002
sha: e0006d5dc71640a10dc9915d27be6442cf92e898
doc_id: 707276
cord_uid: v8dghw17

A significant number of SARS-CoV-2 (COVID-19) pandemic patients have developed chronic symptoms lasting weeks or months which are very similar to those described for myalgic encephalomyelitis/chronic fatigue syndrome. This paper reviews the current literature and understanding of the role that mitochondria, oxidative stress and antioxidants may play in the understanding of the pathophysiology and treatment of chronic fatigue. It describes what is known about the dysfunctional pathways which can develop in mitochondria and their relationship to chronic fatigue. It also reviews what is known about oxidative stress and how this can be related to the pathophysiology of fatigue, as well as examining the potential for specific therapy directed at mitochondria for the treatment of chronic fatigue in the form of antioxidants. This review identifies areas which require urgent, further research in order to fully elucidate the clinical and therapeutic potential of these approaches.

A significant proportion of patients recovering from the current SARS-CoV-2 pandemic, termed 'long-haulers' or 'Long COVID', are reporting a broad range of persistent and debilitating symptoms centred around fatigue but also including symptoms such as 'brain fog', pain, breathlessness, and dysrhythmias, that have extended several months into the post infection period. 1, 2 These symptoms are a characteristic of an already well-documented, potentially devastating and largely unexplained post-viral illness, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This disease is already known to be associated with other viral infections such as Epstein Barr or glandular fever. 3 ME/CFS is a disease of unknown pathophysiology affecting 0.2-2% of the world's population. 4, 5 It is characterised by severe post-exertional fatigue that is not relieved by rest, and as well as pain, severe cognitive dysfunction, insomnia and/or lack of restful sleep, and sensitivity to light and sound, lasts for longer than six months. 6 There is now growing belief that, with millions of SARS-CoV-2 infections worldwide, there will be a spike in ME/CFS, with some people's post viral fatigue developing into the a long term illness that is symptomatically the same as ME/CFS -the unknown question is how many will be affected?

Knowing how many ME/CFS patients there are is difficult: withdrawal from society is common, 7 especially as one in four individuals can be bed-or house-bound lifelong, and many more whilst in the acute phase. 4, 5 Demographic data collection is also hampered because there is no simple diagnostic test for this disease, (twenty published, differing clinical definitions exist). 4 It is approximately two to six times more common in females than males, 8 and affects all ages, socio-economic groups, ethnic groups and geographical locations. 4 It is unknown, as yet, whether the 'long-haulers' from SARS-CoV-2 infections with ME/CFS like symptoms will share the same gender bias and other characteristics.

Similar conditions to ME/CFS have been known for the last two centuries but not recognised as such. 9 In 2019, the Senate of the United States passed a resolution acknowledging that ME/CFS was a serious disease that affected many people and in great need of more research 10 . Spurred on by the SARS-CoV2 pandemic, research into ME/CFS may see such a resurgence. This would be a cruel irony for long-term ME/CFS sufferers if their condition, which has taken so long to be acknowledged as a serious debilitating disease, now gets ready acceptance through COVID-19.

The lack of a known aetiology or pathophysiology, the variability in the symptoms and the lack of outward physical signs of the illness have all contributed to the societal stigma of ME/CFS. 11 It has often been referred to as an 'invisible disease', [13] [14] [15] as people may appear outwardly healthy and well, but be severely ill. 11, 15 Previous classification of ME/CFS as a psychiatric disorder has hindered the care of sufferers of the disease and their interactions with their physicians and the public for many years. 15, 16 It is hoped the SARS-CoV-2 'longhaulers' will not have to undergo these experiences before their illness is properly acknowledged. A 2016 survey found that 60% of affected individuals were not diagnosed for at least one year and this delay can worsen the psychosocial impacts of the disease. 4 These diagnostic difficulties make it hard to know whether the syndrome is a single disease entity with a range of symptoms, rather like multiple sclerosis (MS), or rather several different diseases with very similar and overlapping symptomatology. For example, Booth et al 17 J o u r n a l P r e -p r o o f argues for two or more distinct pathophysiologies that are grouped together as ME/CFS. ME/CFS can have a number of initiating triggers, the most common being a viral infection.

The focus of this review is the links between some of the dysfunctional pathways found in ME/CFS -specifically mitochondrial dysfunction and oxidative stress -and the possible therapeutic effects of antioxidants levels upon these pathways. Simple remedies like antioxidants that are readily available and that can control oxidative stress might prove helpful to improve the lives of ME/CFS patients, as well as those suffering from post-viral illness as a result of SARS-CoV2 infections before other therapies become available.

Mitochondria are organelles that are present in every cell of the body and produce 90-95% of the body's total energy. Mitochondrial respiration produces the energy-carrier adenosine triphosphate (ATP) which drives all the necessary chemical reactions in the body. Cells only contain a small steady state concentration of ATP molecules in cells which needs to be constantly re-generated because of energy demands. This is done by oxidative phosphorylation (OXPHOS) or by glycolysis. 18 Maximal mitochondrial respiration increases with stress, and there can be up to a 100-fold increase in ATP consumption during vigorous activity compared with sleep. Mitochondria are also involved in a wide range of other important cellular actions including redox signalling and cell danger responses. 19, 20 Dysfunction in any of these functions may possibly account for clinical symptoms in ME/CFS, 20 however, mitochondrial bioenergetics is the main area of focus of this review, because dysfunction in mitochondrial respiration and metabolic changes have been found in ME/CFS, 21-23 and these give a biologically plausible link to some of the symptoms seen in ME/CFS. 24 A recent review 25 has looked at mitochondrial changes in ME/CFS patients compared to healthy controls across 19 studies. They concluded that it was difficult to establish the role of mitochondria in the pathology of ME/CFS due to inconsistencies across the published studies. They argued for future studies to be well-designed, with patients diagnosed with the same ME/CFS clinical case definition and with analyses using the same methods. Despite this review, we argue that there is evidence of mitochondrial disturbances in ME/CFS and our review focuses on the potential of exploiting these for therapeutic approaches to alleviating both this complex disease and for SARS-CoV-2 chronically ill patients.

The search for peer-reviewed articles was conducted using Medline and Google Scholar up to March 2020. The following search terms were used: myalgic encephalomyelitis/chronic fatigue syndrome, coenzyme Q10 (CoQ10), MitoQ, bioenergetic health index (BHI), oxidative stress, mitochondrial dysfunction. Variations of these terms were used to ensure all possible papers were found. Inclusion criteria included the English language.

A growing body of literature has investigated mitochondrial bioenergetics in ME/CFS patients, and is reporting evidence of mitochondrial dysfunction 21,26,27 but with varying results. 25,28 Since mitochondria produce most of the body's energy, they could contribute to ME/CFS symptoms of muscle pain, weakness and cognitive decline. 29 Mitochondrial dysfunction found with classical mitochondrial disease caused by genetic mutations, share symptoms of fatigue, muscle weakness, cognitive decline and a waxing and waning pattern such as seen in ME/CFS. 29 A range of different markers has been used to measure mitochondrial dysfunction in ME/CFS including the levels of certain mitochondrial proteins, 30 production of ATP 17,27,31 and more recently, oxygen consumption of live plated cells using a new technology with the Seahorse Analyzer. 21,22,32 The earliest evidence of mitochondrial dysfunction in ME/CFS was structural changes seen in the skeletal muscle cell mitochondria. 33 This study observed branching and fusion of cristae within the mitochondria, and variable shape and size in these patients.

Lawson et al 34 also found condensation of cristae, but no difference in the shape and size of the mitochondria in peripheral blood mononuclear cells (PBMCs). Both studies concluded that the increased energy demand in ME/CFS caused this excess branching of cristae in mitochondria.

Dysfunctional energy producing pathways have been shown in ME/CFS. 17 Tomas et al 21 found that OXPHOS in PBMCs of ME/CFS patients was significantly depressed when compared to controls, and Booth et al 17 found decreased ATP production by OXPHOS. Missailidis et al 22 determined that ATP synthesis, as a percentage of basal respiration, was decreased in ME/CFS compared to controls which suggested a defect in ATP synthase (complex V) in ME/CFS. They inferred this was causing compensatory increases in the rest of the electron transport chain (ETC) (Figure 1 ), as they found increased levels of other complexes: this suggested mitochondria were unable to increase energy from baseline when required. Two studies 21,35 found mitochondria had a lower reserve capacity for energy production in ME/CFS compared to healthy controls, and also suggested mitochondria in ME/CFS are unable to meet energy demands during exercise or acute stress, giving a potential reason for the severe post-exertional fatigue seen in patients.

Lawson et al 34 and Tomas et al 32 found no differences in the levels of specific complexes I-IV of the ETC between ME/CFS and healthy controls, despite finding changes in OXPHOS as a whole in their previous paper. 21 They suggested that any dysfunction, therefore, was not due to these complexes but instead to an external stimuli or other cause such as oxidative damage.

Oxidative damage may be a contributor to the dysfunction seen in mitochondrial pathways. 36 Castro-Marrero 37 reported higher lipid peroxidation as a cause of lowered ATP levels in ME/CFS compared to healthy controls. Morris 

Oxidative stress is a condition of increased amounts of reactive oxygen/nitrogen species. It is an important pathological feature of many acute and chronic diseases as well as the normal aging process. Oxidative stress results from an imbalance between free radicals and antioxidants which causes an increase in free radicals. 37 Free radicals have an additional unpaired single electron, which is unstable and can cause damage to biological proteins and DNA. 39 Free radicals are also produced in normal physiological cell action and signalling. 40 Reactive oxygen species (ROS) are molecules which include free radicals and at least one oxygen atom, such as superoxide or hydrogen peroxide. Antioxidants are scavengers that remove free radicals and are necessary to prevent cellular damage. 39 Mitochondria are a major producer of ROS in the cell, which makes them very susceptible to damage by oxidative stress. 40 In the mitochondrial ETC, electrons en route to oxygen may be diverted in the conversion of oxygen into superoxide. 41 In the mitochondria there are enzymes and coenzymes, such as vitamin E and CoQ10, that remove ROS to prevent damage. If there is damage or dysfunction in the ETC and/or in the ROS-removal system of mitochondria -for example with low levels of CoQ10 -ROS will increase causing further damage. 40

Increased oxidative stress is important in causing and perpetuating a range of pathologies. 42 Jammes et al 43 showed increased markers of oxidative stress in 38 ME/CFS participants and also showed these individuals had greater oxidative stress after exercise. Richards et al 44 also found an association between increased levels of oxidative stress and ME/CFS symptoms in 33 patients. Castro-Marrero et al 37 found increased signs of oxidative damage and decreased antioxidants (CoQ10) in mitochondria from patients with ME/CFS. Miwa and Fujita 45 found levels of oxidative stress were increased in the relapse state of ME/CFS. Oxidative stress found in ME/CFS could be contributing to mitochondrial dysfunction, inflammatory pathways, and brain dysfunction. 36 Suitable biomarkers of oxidative modifications of disease are oxidation products that are stable, can be measured, and which correlate with disease severity so that they can be used as 

As more knowledge of the mitochondrial effects has been learnt, potential treatments are being targeted to improve mitochondrial health. [47] [48] [49] [50] [51] [52] [53] [54] [55] Teitelbaum et al 50 has investigated the effect of D-ribose, the sugar moiety of ATP that stimulates energy production, on ME/CFS symptoms in an uncontrolled, open-label study. They found significant improvement in fatigue as measured by visual analogue scales. ME/CFS patients taking methylphenidate (Ritalin®) with vitamins and minerals which support mitochondrial function, reported some improvement in fatigue scores, although this was non-significant when compared to placebo. 51 In an uncontrolled, open-label study, 45% of participants had reduced fatigue when treated with sodium dichloroacetate, a pyruvate dehydrogenase/ glycolysis inhibitor 52 .

These studies may be relevant to SARS-CoV-2 recovering patients

CoQ10 (also called ubiquinone) is a potential treatment under investigation. It is an important antioxidant in the mitochondria. CoQ10 is the only lipid-soluble antioxidant that is endogenously synthesised in humans. 56 It consists of a quinone head which can complete reduction-oxidation reactions and a long polyisoprenoid lipid tail making it extremely hydrophobic; this allows it to move freely within the phospholipid bilayer. 56 Ubiquinol (reduced CoQ10) acts as an antioxidant by reducing ROS, or by regenerating other antioxidants such as vitamin E. 57 After neutralising an oxygen radical, enzymes in the ETC can recycle and reduce CoQ10 back to ubiquinol. J o u r n a l P r e -p r o o f A significant proportion of CoQ10 (50%) is found in the mitochondrial membranes, 58 but it is also present in all membranes of the body and in the plasma where it is carried in the lipoproteins low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL). 59 CoQ10 is found in the highest concentrations in highly metabolic tissues such as the heart, liver and muscle. 58 When a person is well, quantities of CoQ10 in tissues are thought to be sufficient due to the endogenous production. 69 Beal 70 suggested that the level of CoQ10 in membranes reaches a saturation level in young animals, so that supplementation with CoQ10 does not further increase brain tissue levels. CoQ10 levels did increase in the brain tissue of older individuals and it was suggested that supplements may be beneficial in humans with decreased synthesis such as the elderly or for those with primary CoQ10 deficiency or other diseases. 71 can occur in ME/CMS.

There is reported evidence that CoQ10 levels are decreased in ME/CFS. 37 CoQ10 has been shown to restore respiration and act as an antioxidant. 79 Oral supplementation of CoQ10 has been researched in low-CoQ10 conditions including J o u r n a l P r e -p r o o f mitochondrial disease, 80 neurodegenerative diseases 81 and ME/CFS. 47 A systematic review 82 on sixteen studies of the effects of CoQ10 supplementation on fatigue for both healthy and cohorts with disorders, concluded that CoQ10 was better at decreasing fatigue in some disorders such as fibromyalgia and statin-related fatigue rather than ME/CFS.

there was a non-significant trend for decreased perception of fatigue following exercise when CoQ10 was taken. They did find significant improvement in physical testing in CoQ10supplemented groups compared to control groups, and suggested it was due to its antioxidant or OXPHOS roles. However, Orlando et al 65 Bioavailability may account for this confusion (at least in part). CoQ10 has low bioavailability, due in part to its low water solubility and high molecular mass (M=863 g/mol), which may explain why supplement studies have not always been consistent in producing clinical effects. It is also better absorbed if taken with a fatty meal, like other lipidsoluble supplements such as vitamin E. 58 Langsjoen and Langsjoen 84 found that ubiquinol had a greater bioavailability than ubiquinone in healthy subjects. Vitetta et al 67 also showed a non-significant trend for greater plasma CoQ10 levels at 2 hours after ubiquinol capsule J o u r n a l P r e -p r o o f supplementation compared to ubiquinone capsules in healthy individuals. Therefore, when assessing whether CoQ10 supplements might be beneficial for ME/CFS, the oxidative state of CoQ10 is important as well as the mode of administration.

Another important aspect to consider is the uptake of CoQ10 by tissues from plasma supplementation. In many clinical trials the extent to which CoQ10 enters cells is unknown. It has been found in rodent models that CoQ10 supplementation can increase tissue levels in the liver and spleen, but much higher doses are needed to increase levels in brain and muscle tissue. 58 Niklowitz et al 85 found that supplementing with CoQ10 increased levels in white blood cells and platelets but not in red blood cells. This low uptake in highly metabolic tissues may be a limitation of CoQ10 supplementation, as these are the tissues most influenced by CoQ10 deficiency. 56 Knowing how the molecule distributes across body tissues may be critical for CoQ10 to be used as an effective treatment for ME/CFS.

A CoQ10 analogue, mitoquinol mesylate (MitoQ ® 86 ), developed originally as a tool to target molecules to mitochondria, 87 is a powerful antioxidant and may be helpful in ME/CFS. 78, 87 It is now sold commercially as a supplement to improve health, energy levels and promote healthy aging. MitoQ is known 'to manipulate mitochondrial ubiquinone content in vitro. 87 It has better bioavailability than CoQ10 due to its higher water-solubility. MitoQ consists of a CoQ10 molecule covalently attached to a lipophilic triphenylphosphonium (TPP+) cation.

The positive charge allows MitoQ to accumulate in the negatively charged mitochondria 88 at a concentration 50-1000 times higher than CoQ10. 87 This higher accumulation in the mitochondria and higher bioavailability accounts for its much lower recommended daily supplemental dosage of 10 to 20 mg compared to 200 mg for CoQ10. Thus, MitoQ may be a better candidate for mitochondrial therapy compared to CoQ10, as it may overcome the bioavailability and pharmacodynamic challenges of CoQ10 described above.

In the mitochondria, MitoQ is reduced by complex II of the ETC to form its reduced or ubiquinol state, becoming an antioxidant. 79, 87, 88 Unlike CoQ10, it cannot be easily reduced by complex I or oxidised by complex III because the TPP+ tail stops effective binding to these complexes. MitoQ does not restore respiration in the electron transport chain/ OXPHOS as

CoQ10 does, and is therefore not consumed by this process, allowing higher concentrations of its reduced state to persist within the mitochondria. 89 Kelso et al 87 including a lack of ability to confirm the diagnosis, the usage of self-reported data and an inability to confirm compliance with the study. By contrast, another group of participants who took MitoQ without a matching placebo group, by purchasing the supplement themselves, found significant results and a reduction in clinical symptoms. So far, this online study is the only published study investigating MitoQ for ME/CFS.

The Bioenergetic Health Index (BHI) is an emerging measure in biochemistry that has been referred to as the 'new BMI' by the American Physiological Society. 95 It is a representation of mitochondrial health derived from calculating the 'spare respiratory capacity' multiplied by the 'ATP production of mitochondria under stress', divided by the 'measured proton leak' multiplied by the 'non-mitochondrial respiration' (glycolysis). Chacko et al 96 discussed the use of BHI as a marker of disease progression in particular for areas such as cancer, cardiometabolic syndromes and neurodegenerative diseases, which are now being found to be J o u r n a l P r e -p r o o f affected by mitochondrial dysfunction. 97, 98 BHI is sensitive to oxidative stress and therefore may reflect changes in oxidative stress in these diseases. 96 BHI may help predict who is more susceptible to these diseases and who may benefit from emerging therapies targeting mitochondrial health. For example, post-cardiac surgery patients with the larger decreases in BHI values measured in leucocytes collected from their pericardial fluid were more likely to have cardiac complications (atrial fibrillation), than those with less significant changes in BHI values. [99] [100] [101] [102] [103] [104] As mitochondrial dysfunction and oxidative damage have been implicated in ME/CFS, 28,29 BHI could be a potential biomarker for revealing how well the mitochondria are functioning over time and whether mitochondrial therapies such as MitoQ could be useful in ME/CFS. Only three analyses of BHI with ME/CFS patients have been completed with contradictory results. 21, 22, 32 Key papers regarding mitochondrial functions, oxidative stress and supplementation trials with ME/CFS patients are summarised in Table 1 .

The relatively high proportion of people chronically infected with SARS-CoV-2 ('the long haulers'), who do not make a straight-forward recovery in the post viral period of their illness, almost certainly reflects damage done by the host response to the initial infection. A severe body response such as a cytokine storm can give rise to oxidative and inflammatory damage and generalised oxidative stress, and this suggests that the antioxidant therapies discussed in this review might be beneficial. Antioxidant therapy is known to improve the levels of the abundant natural antioxidant, glutathione (which is important for redox balance), and to strengthen the immune response. 105 Physiological changes in SARS-CoV-2 that enhance the production of reactive oxygen species could be ameliorated by free radical scavengers. 106 Oxidative stress and ongoing pathogenesis in SARS-CoV-2 are almost certainly linked. 107 

Research into mitochondrial function of ME/CFS has been increasing in recent years and appears to hold potential for better understanding this enigmatic disease that may be increasing its prevalence as a result of the SARS-CoV-2 pandemic. 

I'm a COVID-19 long-hauler and an epidemiologist -here's how it feels when symptoms last for months

The Conversation

The lasting misery of coronavirus long-haulers [Internet]. Nature

Chronic fatigue syndrome after infectious mononucleosis in adolescents

ME/CFS/PVFS an exploration of the key clinical issues

Onset patterns and course of myalgic encephalomyelitis/chronic fatigue syndrome. Front Pediatri

Chronic fatigue syndrome/ME: symptoms, diagnosis, treatment

The expressed needs of people with chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review

A SWATH-MS analysis of myalgic encephalomyelitis/chronic fatigue syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction

Board on the Health of Select Populations, Committee on the syndrome: redefining an illness

United States Senate. A resolution supporting the goals of international myalgic encephalomyelitis/chronic fatigue syndrome awareness day S. Res. 225. 116 th Congress

Stigma in myalgic encephalomyelitis and its association with functioning. Fatigue

The illness people can't see: living with Chronic Fatigue Syndrome

The Spinoff

What is invisible illness? (+ how to explain it to others

But you look so good: living with an invisible illness

Chronic fatigue syndrome/myalgic encephalopathy: a knowledge-based approach to an indeterminate illness

Chronic fatigue syndrome: labels, meanings and consequences

Mitochondrial dysfunction and the pathophysiology of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)

Fundamentals of biochemistry. 4 th

Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia?

What is oxidative stress?

Antioxidants in health and disease

The role of mitochondria in reactive oxygen species metabolism and signaling

How mitochondria produce reactive oxygen species

Oxidative stress, aging, and diseases

Chronic fatigue syndrome: acute infection and history of physical activity affect resting levels and response to exercise of plasma oxidant/antioxidant status and heat shock proteins

Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome

Fluctuation of serum vitamin e (α-tocopherol) concentrations during exacerbation and remission phases in patients with chronic fatigue syndrome

Biomarkers of Oxidative Damage in Human Disease

Does oral coenzyme Q 10 plus NADH supplementation improve fatigue and biochemical

Biochemistry of mitochondrial coenzyme Q biosynthesis

Molecular diagnosis of coenzyme Q10 deficiency

Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics

Age-related changes in the lipid compositions of rat and human tissues

Coenzyme Q and its role in the dietary therapy against aging

Coenzyme Q10 in the diet--daily intake and relative bioavailability

Coenzyme Q10 serum concentration and redox status in European adults: influence of age, sex, and lipoprotein concentration

Plasma coenzyme Q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults

Hormonal influence on coenzyme Q 10 levels in blood plasma

Effect of ubiquinol supplementation on biochemical and oxidative stress indexes after intense exercise in young athletes

Physical activity affects plasma coenzyme Q10 levels differently in young and old humans

The plasma bioavailability of coenzyme Q10 absorbed from the gut and the oral mucosa

Coenzyme Q10 and heart failure

Metabolism and function of coenzyme Q

Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases

Coenzyme Q -biosynthesis and functions

Is coenzyme Q a key factor in aging?

Heterogeneity of coenzyme Q10 deficiency: patient study and literature review

Biochemical Assessment of Coenzyme Q10 Deficiency

Isoprenoid pathway dysfunction in chronic fatigue syndrome

Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related J o u r n a l P r e -p r o o f to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder

Biochemical diagnosis of Coenzyme Q10 deficiency

Effect of coenzyme Q10 and MitoQ on mitochondrial function in myalgic encephalomyelitis/chronic fatigue syndrome

University of Otago

Interactions of mitochondriatargeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species: implications for the use of exogenous ubiquinones as therapies and experimental tools

Treatment of mitochondrial disorders: antioxidants and beyond

Coenzyme Q10 depletion in medical and neuropsychiatric disorders : potential repercussions and therapeutic implications

Effect of coenzyme Q10 supplementation on fatigue: a systematic review of interventional studies

Antifatigue effects of coenzyme Q10 during physical fatigue

Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone

Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage

The power is yours: world-first, positively-charged, CoQ10 to help power energy, health and immunity

Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties

Delivery of bioactive molecules to mitochondria in vivo

Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases

Agerelated endothelial dysfunction in human skeletal muscle feed arteries: the role of free radicals derived from mitochondria in the vasculature

Animal and human studies with the mitochondria-targeted antioxidant MitoQ

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients

Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

Could the bioenergetic health index become the next BMI?

The Bioenergetic Health Index: a new concept in mitochondrial translational research

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Mitochondrial dysfunction and molecular pathways of disease

Decreased Bioenergetic Health Index in monocytes isolated from the pericardial fluid and blood of postoperative cardiac surgery patients

Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome

Abnormalities of AMPK activation and glucose uptake in cultured skeletal muscle cells from individuals with chronic fatigue syndrome

Changes in the transcriptome of circulating immune cells of a New Zealand cohort with Myalgic Encephalomyelitis/ chronic fatigue syndrome

Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions

Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise

Pérez-Torres I. Is antioxidant therapy a useful complementary measure for Covid-19 treatment? An algorithm for its application

Prospects for the use of regulators of oxidative stress in the comprehensive treatment of the novel Coronavirus Disease (COVID-19) and its complications

Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection

Tackle the free radicals damage in COVID-19

N-acetylcysteine: a potential therapeutic agent for SARS-CoV-2

A new clinical trial to test high-dose vitamin C in patients with COVID-19

Figure legends: Figure 1. Electron transport chain on the inner mitochondrial membrane. Electrons move from carriers NADH and FADH2 to oxygen, the final acceptor

Complex I or Complex II carrying electrons to Complex III. The electrons then are carried from Complex III to Complex IV by cytochrome C (labelled Cyt C, green). NADH: Reduced J o u r n a l P r e -p r o o f nicotinamide adenine dinucleotide; FADH2: Reduced flavin adenosine dinucleotide